NEUP

Business Context and Reporting Period

Company: Neuphoria Therapeutics Inc. (formerly Bionomics Limited)

Reporting Period: Quarterly period ended December 31, 2024 (Six months ended December 31, 2024)

Corporate Status: The Company completed a redomiciliation from Australia to Delaware on December 23, 2024, becoming a U.S. domestic issuer. It is a clinical-stage biotechnology company focused on neuropsychiatric disorders, primarily advancing BNC210 for Social Anxiety Disorder (SAD) and Post-Traumatic Stress Disorder (PTSD). The Company is classified as a "smaller reporting company" and an "emerging growth company."

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Generation: The Company recorded $662,715 in revenue for the six months ended December 31, 2024, compared to zero in the prior year. This was driven by a milestone payment from Carina Biotech Pty Ltd.
• Reduced Net Loss: Net loss decreased significantly to $2.75 million from $10.03 million year-over-year. This improvement was primarily due to a $3.68 million gain on fair value adjustments related to the accompanying warrant liability and a $0.35 million gain on foreign currency transactions.
• Operating Expenses: Total operating expenses decreased by approximately $2.09 million to $7.93 million. Research and Development (R&D) expenses dropped 29% to $3.64 million, and General and Administrative (G&A) expenses dropped 12% to $4.30 million, attributed to reduced clinical trial expenditures and personnel turnover.
• Liquidity Position: Cash and cash equivalents declined by approximately $8.27 million during the period, reflecting ongoing operational burn despite the reduction in net loss.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has determined there is "substantial doubt" about the Company's ability to continue as a going concern for twelve months following the issuance date. Current cash is projected to fund operations only into late Q4 of fiscal year 2025.
• Subsequent Milestone Payment: On February 12, 2025, the Company announced it is due to receive a $15 million milestone payment from Merck & Co., Inc., triggered by the initiation of a Phase 2 clinical trial for MK-1167. Management expects this, combined with existing cash and an ATM facility, to extend funding into Q4 of fiscal 2026.
• Redomiciliation Costs: The Company incurred professional fees of approximately $0.7 million related to the redomiciliation to Delaware and paid a $0.4 million termination fee to Citibank for the depositary agreement.
• Warrant Liability: A significant non-cash gain of $3.85 million was recognized due to the change in fair value of the accompanying warrant liability, which decreased from $4.66 million to $0.81 million.
• Risks: Key risks include the need for additional capital, clinical trial outcomes, regulatory approvals, and potential dilution from future equity offerings.

Investor Verification Checklist

• Cash Runway: Verify the timing and certainty of the $15 million Merck milestone payment to confirm the extension of the cash runway into 2026.
• Going Concern Status: Assess the Company's ability to raise additional capital if the Merck payment is delayed or if operating costs exceed projections.
• Warrant Liability Volatility: Monitor the fair value of the outstanding warrant liability ($810,125), as fluctuations will continue to impact reported net income/loss without affecting cash flow.
• Redomiciliation Impact: Confirm the completion of all regulatory and administrative steps related to the transition from Bionomics Limited to Neuphoria Therapeutics Inc.
• ATM Facility Utilization: Review the utilization of the new "at-the-market" (ATM) offering agreement with H.C. Wainwright & Co., LLC, which allows for up to $3.56 million in sales.